Insulet Corporation $PODD Shares Sold by Baird Financial Group Inc.

Key Points

• Baird Financial Group reduced its Insulet stake by 12.1% in the second quarter, selling 16,089 shares and retaining 117,326 shares worth approximately $17.9 million.
• Other major institutional investors increased their exposure, including California State Teachers Retirement System, which added more than 14.4 million shares, while BlackRock initiated a position valued at over $1 billion.
• Insulet reported better-than-expected quarterly results, with EPS of $1.66 and revenue of $801.7 million, up 23.5% year over year. Shares opened at $131.96, while analysts maintained a consensus “Hold” rating with a $195.40 target price.

Baird Financial Group Inc. decreased its holdings in Insulet Corporation (NASDAQ:PODD - Free Report) by 12.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 117,326 shares of the medical instruments supplier's stock after selling 16,089 shares during the period. Baird Financial Group Inc. owned approximately 0.17% of Insulet worth $17,863,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of PODD. California State Teachers Retirement System raised its stake in shares of Insulet by 13,901.9% in the 2nd quarter. California State Teachers Retirement System now owns 14,562,256 shares of the medical instruments supplier's stock valued at $2,217,103,000 after acquiring an additional 14,458,254 shares during the period. BlackRock Inc. acquired a new stake in Insulet in the 2nd quarter valued at $1,018,582,000. State Street Corp increased its holdings in Insulet by 2.1% in the 4th quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier's stock valued at $896,916,000 after purchasing an additional 65,317 shares in the last quarter. Geode Capital Management LLC increased its holdings in Insulet by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier's stock valued at $568,274,000 after purchasing an additional 41,019 shares in the last quarter. Finally, Invesco Ltd. raised its position in Insulet by 10.5% in the fourth quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier's stock valued at $420,835,000 after purchasing an additional 141,167 shares during the period.

Insulet Stock Down 2.0%

Shares of NASDAQ:PODD opened at $131.96 on Friday. Insulet Corporation has a 12-month low of $126.40 and a 12-month high of $354.88. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. The firm has a market cap of $9.15 billion, a PE ratio of 24.67, a price-to-earnings-growth ratio of 1.06 and a beta of 1.08. The company has a fifty day simple moving average of $152.36 and a 200 day simple moving average of $173.92.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, topping the consensus estimate of $1.47 by $0.19. The company had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The company's revenue was up 23.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, equities research analysts anticipate that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on PODD shares. Benchmark reduced their price objective on Insulet from $250.00 to $185.00 and set a "buy" rating on the stock in a research note on Thursday, August 6th. Stifel Nicolaus lowered their target price on Insulet from $225.00 to $180.00 and set a "buy" rating for the company in a research note on Thursday, August 6th. Evercore set a $180.00 target price on Insulet in a report on Monday, July 6th. William Blair started coverage on Insulet in a research report on Wednesday, May 20th. They set an "outperform" rating on the stock. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Insulet in a report on Tuesday, June 23rd. They issued a "buy" rating and a $190.00 price target for the company. Fourteen analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $195.40.

Insulet Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company's principal product platform is Omnipod, a tubeless, wearable insulin pump system. Omnipod products include the disposable, wearable Pod and related management and smartphone-based technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.